PlainPill

Lisdexamfetamine

Also known as Vyvanse, Elvanse

The short answer. People are split on Lisdexamfetamine — 41% of 281 say it helped. It is most often used for focus: 87% of 200 reports say that improved. It is well studied — 58 meta-analyses on PubMed. The most common complaint is anxiety.

What users report
41%helped281 reports · high confidence
114 helped114 mixed53 didn't help

From 439 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
58
meta-analyses
112
RCTs
648
papers
Prescription medication. These are self-reported experiences, not dosing or treatment advice. Prescription drugs have real side effects and interactions — start, stop or change them only with a doctor. Share of positive reports is not a measure of safety.

What Lisdexamfetamine does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 58 meta-analyses on PubMed ↗ · 112 randomized trials ↗

Lancet Psychiatry · 2018 · Meta-analysis / systematic review
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis

Conclusion: Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.

PubMed 30097390 ↗
PLoS One · 2020 · Meta-analysis / systematic review
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis

Conclusion: Overall, despite a class effect of improving clinical response relative to placebo, there were few differences among the individual ADHD pharmacotherapies, and most studies were at risk of at least one important source of bias. Furthermore, the certainty of the evidence was very low to low for all outcomes, and there was limited reporting of long-term adverse events. As such, the choice between ADHD pharmacotherapies may depend on individual patient considerations, and future studies should assess the long-term effects of individual pharmacotherapies on patient-important outcomes, including qu

PubMed 33085721 ↗
Registered clinical trials

126 human trials on ClinicalTrials.gov test Lisdexamfetamine — 94 completed, 5 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

US legal status (DEA)

Lisdexamfetamine is a Schedule II controlled substance in the US. DEA controlled-substance list ↗

FDA drug label

Boxed warning (the FDA's strongest label warning): “ABUSE, MISUSE, AND ADDICTION Lisdexamfetamine dimesylate has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including lisdexamfetamine dimesylate, can result in overdose and death, and…”

Full label on DailyMed (NIH) ↗

FDA recalls

11 recalls of products named for Lisdexamfetamine. Most recent:

  • 2025-11-05 · Class II: Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station… record ↗
  • 2025-09-03 · Class II: Labeling: Label Mix-up. A bottle labeled as Lisdexamphetamine Dimesylate Capsules 40mg, contained Lisdexamphetamine Dimesylate Capsules 30mg. record ↗
  • 2025-07-23 · Class II: Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 9 month long term stability station… record ↗

Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗

Reports to the FDA about the drug (FAERS)

34,600 adverse-event reports mention Lisdexamfetamine. Most often reported:

  • Drug ineffective · 4,950
  • Fatigue · 2,150
  • Off label use · 2,115
  • Anxiety · 1,944
  • Headache · 1,857
  • Nausea · 1,642

Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗

US government research funding (NIH)

NIH has funded 4 research projects with Lisdexamfetamine in the title, $3,127,139 in total (2009–2023). NIH RePORTER ↗

Plain-language guides from the US government: MedlinePlus: Lisdexamfetamine ↗

Dosage people report

We don't list doses for prescription medications. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

anxiety ×23insomnia ×14fatigue ×10irritability ×9tolerance ×7appetite loss ×5jitteriness ×4depression ×4

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“It's been a game changer for my focus and energy levels, really brought me back to life.”
HelpedRead the discussion ↗
“I got diagnosed with ADHD and tried Ritalin and Elvanse and they do help somewhat when I need to learn for an exam but I hate the feeling of being on them.”
MixedRead the discussion ↗
“I used vyvanse daily for years. I have not felt pleasure, motivation, or desire in the same way since.”
MixedRead the discussion ↗
“Concerta, Vyvanse (they gave me stimulation and a mood booster but it felt really artificial, left me with more depression when I was not taking it)”
Didn't helpRead the discussion ↗
Read more Lisdexamfetamine reviews →
Top discussions (5)

Lisdexamfetamine compared

Other options for focus

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate